Abstract:Abstract Disclosure: F. Amer: None. S. Ghaith: None. S. Kadiyala: None. M. Xhikola: None. Background: Thionamides can lead to agranulocytosis in 0.1 - 0.5% of patients. This is a severe adverse reaction due to inhibition of myelopoiesis. The proposed mechanism of bone marrow suppression is thought to be due to direct toxicity and/or immune mediated. For methimazole this side effect is seen with doses > 30 mg/day. This is a case of isolated thrombocytopenia in a patient treated with low dose methimazole. Clinical case: 69-year-old man diagnosed with Graves’ disease about 8 years ago was initially started on methimazole 20 mg/day. Later it was decreased to 10 mg/day or lower based on the thyroid function. Baseline platelet count was 140k/μl (130k - 440k/μl). Three years post initiation of methimazole, platelet count decreased compared to baseline but stayed stable between 80k - 115k/μl. Later, from 2018 - 2022 the platelet counts progressively decreased below 80k (as low as 25k/μl). In June 2022 patient was euthyroid on methimazole 10 mg/day but platelets had decreased to 51k/μl, almost half of what they were 6 months prior when the methimazole dose was averaging at 6.4 mg/day but was increased to 10 mg/day due to patient being biochemically hyperthyroid. Different doses of methimazole were attempted including 5 - 10 mg/day. Patient was able to become euthyroid only with 10 mg/day but with each methimazole dose escalation, platelet count would drop. Clinically there was no indication of bleeding. Further work up included unremarkable bone marrow aspirate, normal karyotype, normal flow cytometry, negative antiplatelet antibodies. A screen for antinuclear antibodies was negative, serum protein electrophoresis showed no monoclonal protein. Serum IgG and IgA were normal, but serum IgM was elevated to 499 mg/dl (57 – 359). Immunological studies show a decrease in C3 and C4, suggesting activation of the classical complement pathway. Alternative treatments for hyperthyroidism were discussed including radioactive iodine (RAI) and/or total thyroidectomy. At that time patient categorically refused to undergo any alternative option other than medical therapy. In late 2022 platelet count decreased to 25k/μl, but patient again refused RAI or thyroidectomy, and the decision was made to stop methimazole and start prednisone and cholestyramine to decrease free T4 and prevent further platelet decline. In 2 weeks, platelets improved to 93,000/μl. Currently, patient has agreed to proceed with RAI and will be treated soon. Of note, patient had mild degree of leukopenia with white cell count (WBC) of 4400-5000 /μL. Correlation between the WBC and the methimazole dose was not noted.Conclusion: This case shows selective significant thrombocytopenia in a patient treated with low-dose methimazole (5 - 10 mg/day). The underlying mechanism could be direct toxicity due to dose accumulation over the years in addition to immune mediated mechanisms considering the low C3 and C4 complements and serum IgM increase. Presentation: Friday, June 16, 2023

False Adrenergic Transmitter Release from the Isolated Cat Heart

Comparison of agranulocytosis and anti‐neutrophil cytoplasmic antibody‐associated vasculitis caused by two antithyroid drugs: A pharmacovigilance study using the WHO international database

The Evaluation and Management of Methimazole-Induced Agranulocytosis in the Pediatric Patient: A Case Report and Review of the Literature

Replacing MRSA with wild Staphylococcus aureus

Spontaneous Activity Defines Effective Convergence Ratios in an Inhibitory Circuit

Unusual Synchronous Methimazole-Induced Agranulocytosis And Severe Hepatotoxicity In Patient With Hyperthyroidism: A Case Report And Review Of The Literature

Treatment Challenges of Methimazole-Induced Agranulocytosis in Younger Patients

Propylthiouracil, and methimazole, and carbimazole-related hepatotoxicity

Long-term follow-up of patients with hyperthyroidism due to Graves' disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: a retrospective study

Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism

Effects of Low-dose Methotrexate With Methimazole in Patients With Graves’ Disease: Results of a Randomized Clinical Trial

Recent advances in the management of spinal injuries with paralysis.

Mechanistic Examination of Methimazole-Induced Hepatotoxicity in Patients with Grave’s Disease: a Metabolomic Approach

Comparison of the safety between propylthiouracil and methimazole with hyperthyroidism in pregnancy: A systematic review and meta-analysis

Is there a methimazole dose effect on remission rate in Graves' disease? Results from a long-term prospective study. The European Multicentre Trial Group of the Treatment of Hyperthyroidism with Antithyroid Drugs

Characteristics of Antithyroid Drug-Induced Agranulocytosis in Patients with Hyperthyroidism: A Retrospective Analysis of 114 Cases in a Single Institution in China Involving 9690 Patients Referred for Radioiodine Treatment Over 15 Years.

Docetaxel maintains its cytotoxic activity under hypoxic conditions in prostate cancer cells.

FRI516 Low Dose Methimazole Induced Isolated Thrombocytopenia

THERAPEUTIC EFFECTS OF COMBINATION REGIMENS INCLUDING METHIMAZOLE ON GRAVES HYPERTHYROIDISM: A NETWORK META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

[Monomers of a satellite sequence of chaffinch (Fringilla coelebs L., Aves: Passeriformes) genome contains short clusters of the TTTAGGG repeat].

Treatment and Prevention of Neonatal Anemia.